Navigation Links
Alma Lasers Announces Proposed Initial Public Offering
Date:1/3/2008

BUFFALO GROVE, Ill., Jan. 3 /PRNewswire/ -- Alma Lasers Ltd. ("Alma Lasers") announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to its proposed underwritten initial public offering of its ordinary shares.

The initial public offering is expected to consist of newly issued shares being offered by Alma Lasers and secondary shares offered by certain stockholders. In addition, Alma Lasers expects to grant the underwriters an option to purchase additional ordinary shares to cover over-allotments, if any.

Citigroup Global Markets Inc. and UBS Investment Bank will serve as joint bookrunning managers, William Blair & Company, L.L.C. will serve as lead manager, and Jefferies & Company, Inc. will serve as co-manager for the proposed offering.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement.

Once available, a preliminary prospectus relating to these securities may be obtained by contacting Citigroup Global Markets Inc., Brooklyn Army Terminal, 140 58th Street, Brooklyn, New York 11220, Attn: Prospectus Department or UBS Investment Bank, Prospectus Department, 299 Park Avenue, New York, New York 10171.

About Alma Lasers

Alma Lasers is a global medical technology company that designs, develop
'/>"/>

SOURCE Alma Lasers Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Alma Lasers Answers Lumenis Complaint
2. Smart Balance Announces Conversion of Convertible Preferred Stock
3. IDM Pharma Announces Termination of UVIDEM Development Collaboration and Expected Restructuring in Connection With Evaluation of Strategic Alternatives
4. MQ Associates, Inc. Announces Cash Tender Offer for 121/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Related Consent Solicitation
5. Heska Announces Amended Agreement With AgriLabs
6. Versus Technology Announces Fourth Quarter Results
7. FASgen Announces New Research Discoveries in Lung Cancer
8. Boston Scientific Announces CE Mark Approval for Next-Generation Cardiac Resynchronization Therapy Defibrillator
9. KV Pharmaceutical Company Announces NYSE Listing Extension
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
11. Transition Therapeutics Announces Appointment of Vice-President of Business Development

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...LLAS, Nov. 27 Considere...re only 25 years ago, solid organ transplantation ...o the extraordinary men and women who gathered at ...ders came together from medical centers around the... Regional Transplant Institute (BRTI), one of the ...
(Date:11/27/2009)...BUTZ SHAMIR, Israel, Nov. 27 /PRNewswire-FirstCall... ( "Shamir" ), a leading provider of innovative pr...t, announced today that its board of directors had...amount of US$ 10 million (approximately NIS 37.62 ...ive rate of exchange), or approximately US$ 0.609 ...
(Date:11/27/2009)... , SEATTLE, Nov. 27 Al...d record-high Thanksgiving traffic numbers, with m...sgiving, providing a clear picture of what was ser...verage Thanksgiving meal in 2009 weighed in at 2,2... last year,s feast. According to the Allrecipes si...
(Date:11/27/2009)... Three new interactive anatomy educatio... Wilkins expand health sciences learning opportuni... Durham, NC (Vocus) November 27, 2009 -- M...ns (LWW), a division of Wolters Kluwer Health, tod... education apps on the App Store. Clemente’s...
(Date:11/26/2009)...equestering drug tetrathiomolybdate (TM) has been ...of Wilson disease, a disease caused by an overload...uch is known. Very little, however, is known about...new study led by Northwestern University researche...dimensional structure of TM bound to copper-loaded...
Breaking Medicine News(10 mins):Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3
...n decided to stop admitting patients to the Altrin...ty. The decision been taken by NHS managers// who ... Although patient safety is believed to be respo...he elderly will close soon. The day care clinics, ...
...th the International Women’s Day celebrations, an ...Chennai-based Apollo hospitals. Ms. J. Jayalalitha... health care center on Wednesday. // The hea...t women, diseases such as cancer, AIDS, osteoarthr...
...sal fact is that breastfeeding is the best form of...r breastfeeding or the weaning age affect the risk...various platforms. // A new study on this aspec...in the March issue of the American Journal of Clin...
...nston, professor of psychology and a team of Corne...at different areas of the brain react differently ... upon the emotions attached to the memory. The res...vidence of those encounters. They identified w...
...ther Herceptin refusal case in the UK, a 10-year-o...t cancer is seeking the help from her MP in order ...eatment. Katie Morgan's mother, Susan wants to be ... region has received the letter written by Kate re...
...e widespread awareness being propagated by the Ind...hips, as still most of the people don’t even posse...married Celina was busy knitting dreams of life an...put up a tough fight against the disease and socie...
Other Medicine News:Health News:Want to save the child from obesity introduce infant food early: says a study 2Health News:Cure For Autism Could Be Established Through Hamster Studies 2Health News:Misconceptions Put AIDS Patients In Tight-Spot 2
(Date:11/25/2009)..., , RANCHO CORDOVA, Calif., Nov. 25 /PRNe...diary of American Pacific Corporation (Nasdaq: AP...ental Responsibility and Sustainability Award at t...d by the California Manufacturers and Technology A...sociation (IEA) and the Chemical Industry Council ...
(Date:11/25/2009)..., , HARBIN, China, Nov. 25 /PRNe...nc. ("China Sky One Medical" or "the Company") (Na...utical company developing and producing,over-the-c...RC"), today,announced that the Company recently pa...l of Pharmaceutical and Biological Products ("ICPB...
(Date:11/25/2009)..., , NEW YORK, Nov. 25 /PRNewswire/ ...search report is available in its catalogue: ,,...tive ,, http://www.reportlinker.com/p0164330...ve.html ,, Rising incidence of breast cancer i...a principal factor influencing growth in the mammo...
Breaking Medicine Technology:AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8Howard Dean and Chelsea Green Publishing Utilize iPhone Technology to engage and Mobilize Americans in Healthcare Reform Debate 54615 1Howard Dean and Chelsea Green Publishing Utilize iPhone Technology to engage and Mobilize Americans in Healthcare Reform Debate 54615 2Howard Dean and Chelsea Green Publishing Utilize iPhone Technology to engage and Mobilize Americans in Healthcare Reform Debate 54615 3Howard Dean and Chelsea Green Publishing Utilize iPhone Technology to engage and Mobilize Americans in Healthcare Reform Debate 54615 4Vasogen Receives NASDAQ Notification Related to Minimum Bid Price 13586 1Vasogen Receives NASDAQ Notification Related to Minimum Bid Price 13586 2BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 13583 1BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 13583 2BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 13583 3
...howed Campath May Lead to Overall Survival in Pati...NCISCO, Dec. 9 Bayer HealthCare Pharmaceuticals I...wing that treatment with Campath(R) (alemtuzumab) ...eukemia (CLL) patients who have poor prognostic in...h Annual Meeting of the American Society of Hemato...
...ANCISCO, Dec. 8 Millennium: The Takeda Oncology C...ended follow up of patients from the large, intern... survival improvement for patients with previously...an and prednisone (VcMP). The VELCADE combination ...b-groups, including those with poor prognostic cha...
Other Medicine Technology:Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 2Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 4Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 5Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 6Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 8Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 9Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 10Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: